6. References
- Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials 2016;17:286.
- Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal 2018;198:135-44.
- Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140:e294-e324.
- Arenja N, Mueller C, Ehl NF, et al. Prevalence, Extent, and Independent Predictors of Silent Myocardial Infarction. The American Journal of Medicine 2013;126:515-22.
- Kannel WB, McGee DL. Diabetes and Cardiovascular Disease: The Framingham Study. Journal of the American Medical Association 1979;241:2035-8.
- Qureshi WT, Zhang Z-M, Chang PP, et al. Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study. Journal of the American College of Cardiology 2018;71:1-8.
- The ASCEND Study Collaborative Group. Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine 2018;379:1540-50.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine 2018;380:11-22.
- Djoussé L, Cook NR, Kim E, et al. Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. Circulation 2020;141:784-6.
- Djoussé L, Cook NR, Kim E, et al. Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. JACC Heart Failure 2022;10:227- 34.
- Valensi P, Meune C. Congestive heart failure caused by silent ischemia and silent myocardial infarction. Herz 2019;44:210-7.
- Zannad F, Pfeffer MA, Bhatt DL, et al. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart 2017;103:1156-62.
- Calvo G, McMurray JJV, Granger CB, et al. Large streamlined trials in cardiovascular disease. European Heart Journal 2014;35:544-8.
- Van Staa T-P, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. British Medical Journal 2012;344:e55.
- Huang H, Turner M, Raju S, et al. Identification of Acute Decompensated Heart Failure Hospitalizations Using Administrative Data. American Journal of Cardiology 2017;119:1791- 6.
- McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure diagnoses in administrative databases: A systematic review and meta-analysis. PLoS ONE 2014;9.
- Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985;27:335-71.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer 1977;35:1-39.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. 20. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions (3rd ed.). John Wiley & Sons; 2013.
2022-07-21 HF-ASCEND Main Data Analysis Plan V1.0 [PDF]